These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34015686)

  • 1. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.
    Glimelius B; Stintzing S; Marshall J; Yoshino T; de Gramont A
    Cancer Treat Rev; 2021 Jul; 98():102218. PubMed ID: 34015686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the evolution of systemic chemotherapy in the management of colorectal cancer.
    Gustavsson B; Carlsson G; Machover D; Petrelli N; Roth A; Schmoll HJ; Tveit KM; Gibson F
    Clin Colorectal Cancer; 2015 Mar; 14(1):1-10. PubMed ID: 25579803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.
    Carlsson G; Koumarianou A; Guren TK; Haux J; Katsaounis P; Kentepozidis N; Pfeiffer P; Brændengen M; Mavroudis D; Taflin H; Skintemo L; Tell R; Papadimitriou C
    ESMO Open; 2022 Oct; 7(5):100589. PubMed ID: 36183444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine chemotherapy for metastatic colorectal cancer. Chemical structure, combinations and efficacy.
    Koukourakis G; Kouloulias V; Zacharias G; Koukourakis M
    J BUON; 2010; 15(4):652-9. PubMed ID: 21229625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
    Nakamoto Y; Noda M; Mikami R; Tokunaga Y; Okumoto T; Kawamura T; Fujiwara H; Doi S; Tomita N
    Int J Clin Oncol; 2020 Jul; 25(7):1285-1290. PubMed ID: 32200481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
    Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A
    Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
    Grapsa D; Syrigos K; Saif MW
    Expert Rev Anticancer Ther; 2015; 15(11):1267-81. PubMed ID: 26506906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
    Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of UFT in metastatic colorectal cancer.
    Bennouna J; Saunders M; Douillard JY
    Oncology; 2009; 76(5):301-10. PubMed ID: 19299903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
    Carnaghi C; Zucali P; Garassino I
    Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
    Cartwright T; McCollum D; Boehm KA
    Am J Clin Oncol; 2010 Jun; 33(3):307-13. PubMed ID: 20375835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer: chemotherapy treatment overview.
    Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the treatment of metastatic colorectal cancer.
    Goldberg RM
    Oncologist; 2005; 10 Suppl 3():40-8. PubMed ID: 16368870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
    Ron DA; Vera R; Labandeira CM; Manrique MCA; Núñez MÁ; Cid NG; Mata JG; Montes AF
    Clin Transl Oncol; 2020 Aug; 22(8):1205-1215. PubMed ID: 31898053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New systemic frontline treatment for metastatic colorectal carcinoma.
    Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
    Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.